Phase I Study of Dovitinib (TKI258) in Combination With Gemcitabine and Capecitabine in Advanced Solid Tumors, Pancreatic Cancer and Biliary Cancers
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Dovitinib (Primary) ; Capecitabine; Gemcitabine
- Indications Cholangiocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 28 Oct 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2015, as reported by ClinicalTrials.gov.